Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Mantle Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1037
)
Diffuse Large B Cell Lymphoma (374
)
T Cell Non-Hodgkin Lymphoma (118
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (41
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (1037
)
Diffuse Large B Cell Lymphoma (374
)
T Cell Non-Hodgkin Lymphoma (118
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (41
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(125)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
temsirolimus
Sensitive: A1 - Approval
temsirolimus
Sensitive
:
A1
temsirolimus
Sensitive: A1 - Approval
temsirolimus
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive: A2 - Guideline
venetoclax + ibrutinib
Sensitive
:
A2
venetoclax + ibrutinib
Sensitive: A2 - Guideline
venetoclax + ibrutinib
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
ibrutinib + rituximab + lenalidomide
Sensitive: A2 - Guideline
ibrutinib + rituximab + lenalidomide
Sensitive
:
A2
ibrutinib + rituximab + lenalidomide
Sensitive: A2 - Guideline
ibrutinib + rituximab + lenalidomide
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
ibrutinib + rituximab
Sensitive: A2 - Guideline
ibrutinib + rituximab
Sensitive
:
A2
ibrutinib + rituximab
Sensitive: A2 - Guideline
ibrutinib + rituximab
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + zanubrutinib
Sensitive: A2 - Guideline
rituximab + zanubrutinib
Sensitive
:
A2
rituximab + zanubrutinib
Sensitive: A2 - Guideline
rituximab + zanubrutinib
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + acalabrutinib
Sensitive: A2 - Guideline
rituximab + acalabrutinib
Sensitive
:
A2
rituximab + acalabrutinib
Sensitive: A2 - Guideline
rituximab + acalabrutinib
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
+
Sensitive: A2 - Guideline
+
Sensitive
:
A2
+
Sensitive: A2 - Guideline
+
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
+
Sensitive: A2 - Guideline
+
Sensitive
:
A2
+
Sensitive: A2 - Guideline
+
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
+
Sensitive: A2 - Guideline
+
Sensitive
:
A2
+
Sensitive: A2 - Guideline
+
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login